Onyx Pharmaceuticals (ONXX) reported third quarter earnings of 28 cents per share, well above the Zacks Consensus Estimate of 22 cents as well as 21 cents reported in the year-ago period. The company, along with Bayer AG (BAYRY.PK), developed Nexavar (sorafenib) tablets, an anticancer therapy currently approved and marketed for the treatment of liver cancer and advanced kidney cancer in the US, European Union, Japan and some other countries. Onyx’s earnings come in the form of royalty and collaboration income on Nexavar sales.  For the quarter, Onyx reported revenues of $69.1 million compared to $50.8 million for the same period in 2008 primarily due to an increase in Nexavar sales and royalty revenue and a decline in the drug’s commercial expenses. While revenues increased 36%, a 43.6% rise in operating expenses brought down Onyx’s operating margin by 450 basis points to 14.5%. R&D and SG&A expenses increased ...

Kraft Foods (KFT) reported strong second-quarter results with earnings of 55 cents per share, above the Zacks Consensus Estimate of 48 cents. Quarterly earnings were also up 61.8% year-over-year. However, net revenues for the quarter declined 5.7% year-over-year to $9.8 billion, primarily due to the unfavorable negative 5.6% impact of foreign currency and a negative 0.6% impact from divestitures. Organic revenues increased 0.5%, driven by a 0.7% gain from volume and mix, which was partially offset by negative 0.2% from pricing. In the North American segment (KNAC) sales declined 2.5% year-over-year as gains in U.S. Convenient Meals (5.0%), and U.S. Beverages (1.5%) were fully offset by the declines in U.S. Cheese 10.3%, U.S. Grocery 3.0%, U.S. Snacks 3.3% and Canada & North American Foodservice 4.9%. In the International segment, net revenues in the European Union decreased 11.5% while the top-line in developing markets contracted 8.4%....

Mikhael Gorbachev has penned an article in the New York Times reflecting on how the period since the fall of the Berlin Wall (the 20th anniversary of which will be celebrated on Friday) has not necessarily heralded a less distrustful approach to Russia.  He cites the open letter to  to Barack Obama by Vaclav Havel and other European luminaries in September, counseling the US President to take a firm stand on Russia, and the OSCE resolution equating Stalinism and Nazism as moves demonstrating that latent russophobia is still hampering unity in Europe.To my regret, the events took a different course. This has stalled the emergence of a new Europe. Instead of the old dividing lines, new ones have ...

Recently, Mexican cement maker CEMEX S.A.B. de C.V. (CX) posted decent results for the third quarter of 2009, considering the difficult economy.  Net sales decreased to US$4.2 billion versus US$5.8 billion in the comparable period in 2008, representing a decrease of 27% − or a decrease of 19% when adjusting for the exclusion of the Venezuelan operations − on the sale of the assets in the Canary Islands, besides currency fluctuations.  Lower sales in the quarter were primarily attributable to lower volumes, mainly from the U.S. and Spanish operations, as well as the exclusion of Venezuelan operations and the sale of assets in the Canary Islands.  EBITDA decreased 38% in the quarter to US$806 million from US$1.3 billion in the same period of 2008, or 30% when adjusting for the exclusion of abovementioned assets and currency fluctuations.  Cemex earned US$121 million in the quarter, ...

Recently, Merck (MRK) and Schering-Plough (SGP) received approval from the US Federal Trade Commission (FTC), the Swiss Competition Commission and the Canadian Competition Bureau for their proposed merger. However, the transaction has yet to receive approval from other regulators, including China and Mexico. The deal was approved by the European Union antitrust regulators last week. Shareholders of both the companies have already approved the deal in August. Merck expects to close the proposed merger by year end. The FTC approval has come with the condition that both companies will sell some assets. As a result, Schering-Plough has agreed to sell its rolapitant drug, meant to be used for the treatment for nausea and vomiting in chemotherapy patients to Opko Health Inc. In addition, Merck agreed to sell its interest in Merial Ltd, an animal health joint venture, to its French partner, Sanofi-Aventis ...

The Best Two Ways to Play Canada’s Economy, Currency And Natural Resources

Tony Daltorio, Investment U Research

A vast amount of natural resources. A love of hockey. A penchant for bacon. And liberal use of the word “eh.”

All are associated with Canada, of course. But America’s neighbor to the north boasts another fine trait: an efficiently run economy.

You see, although Canada borders the United States, it takes a completely different approach towards economic policy.

That showed strongly just recently when America stoked protectionist fears by slapping stiff duties on tire imports from China. Yet days later, Canada unveiled plans for a significant move in the opposite direction. Canada aims to abolish all remaining tariffs on imported machinery and equipment used by domestic manufacturers, saving Canadian manufacturers C$250-300 million a year.

And while the United States dithers over

...

There's a very interesting article on euobserver.com about Russia's attempts to re-brand itself as a benign global power in the eyes of Brussels.  The piece reports that news agency Ria-Novosti has apparently engaged the services of low-profile PR consultancy RJI Companies to assist it in softening Russia's image in Europe, in order to justify it having a large say in global affairs.  Apparently a sub-section of this campaign revolves around Stalin rehabilitation and a Soviet makeover:Russian news agency Ria Novosti is rolling out a new public relations campaign in the political capital of the European Union which, according to sources in the PR industry, aims to justify Russia's great power ambitions and improve the image of Joseph Stalin....

Vimovo Demonstrates Benefit Over Naproxen Yesterday, at the American College of Gastroenterology meeting in San Diego, Pozen (POZN) released data from two phase III trials comparing Vimovo (formerly PN400) to enteric-coasted naproxen (ECN) in patients with osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) who are at risk of developing NSAID-associated gastric ulcers. The data demonstrated that patients taking Vimovo experienced significantly greater reduction in severity of dyspepsia (SODA) and overall treatment evaluation for dyspepsia (OTE-DP) compared to patients taking ECN. The OTE-DP results showed 43-46% of the patients on Vimovo reporting positive change at month six vs. only 28-34% on ECN. The results were highly statistically significant. Plus, patients taking Vimovo also had discontinuation rates far below ECN, at 3-5% vs. 11-12%, respectively. The safety of Vimovo was also superior to ECN, with only 2% of the patients experiencing erosive duodenitis as compared to 10-14% for ...

GlaxoSmithKline (GSK) recently received a positive recommendation from the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) for its cervical cancer vaccine, Cervarix. The CDC has recommended that Cervarix should be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic human papillomavirus (HPV) 16 and 18.   The committee also recommended that the vaccine should be used in 11 and 12 year old girls specifically and in girls and young women who have not yet been vaccinated. Cervarix, which received approval in the U.S. recently, is indicated for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic HPV types 16 and 18 for use in girls and young women (aged 10-25).   The ACIP’s recommendation should help increase adoption of the vaccine, which is slated to hit the U.S. market later this ...

Recently, the European Union (EU) approved the proposed $41.1 billion merger between Schering-Plough (SGP) and Merck & Co. (MRK). The deal is awaiting approval from the U.S. Federal Trade Commission. The transaction is expected to close in the fourth quarter of this year. While approving the merger, the EU clarified that the tie-up will not hinder effective competition significantly in Europe, even though both participants in the merger operate in the field of prescription pharmaceuticals. While checking for overlaps in Europe, particularly in the fields of asthma and allergic rhinitis, the European body did not find the products to be close competitors. Consequently, the merger would not be considered to hog the market and choke other companies. As a reminder, Merck filed for EU approval last month after the completion of the sale of its 50% interest in animal health company Merial Limited (Merial) to ...